Microbicides have been evaluated mostly against cell-free HIV-1. Because semen contains both cell-free and cell-associated HIV-1, HIV-1 transmission could occur via either or both sources. Therefore, it is important to examine the antiviral activity of microbicides against cell-associated HIV-1. The cyclic antimicrobial peptide retrocyclin RC-101 has been shown previously to have antiviral activity against cell-free HIV-1, with no associated cellular toxicity. In this article we have examined the antiviral activity of RC-101 against cell-associated HIV-1. The results demonstrate potent antiviral activity of RC-101 against cell–cell HIV-1 transmission in both CD4-dependent and CD4-independent assays against CCR5- and CXCR4-tropic HIV-1, with no cellular toxicity. Furthermore, this antiviral activity was retained in the presence of human seminal plasma. The potent antiviral activity of RC-101 against cell-associated HIV-1 reported here, and the previously reported antiviral activity in cervical tissues, suggest that RC-101 is an excellent and promising microbicide candidate against HIV-1.
Get full access to this article
View all access options for this article.
References
1.
Carballo-DieguezA, SteinZ, SaezHet al.Frequent use of lubricants for anal sex among men who have sex with men: The HIV prevention potential of a microbicidal gel. Am J Public Health, 2000; 90:1117–1121.
GrossM, HolteSE, MarmorMet al.HIVNET Vaccine Preparedness Study 2 Protocol Team. Anal sex among HIV-seronegative women at high risk of HIV exposure. J Acquir Immune Defic Syndr, 2000; 24:393–398.
4.
FiscusSA, PilcherCD, MillerWCet al.Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis, 2007; 195:416–424.
5.
GuptaP, MellorsJ, KingsleyLet al.High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol, 1997; 71:6271–6275.
6.
VernazzaPL, EronJJ, CohenMSet al.Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS, 1994; 8:1325–1329.
7.
VernazzaPL, EronJJ, FiscusSA. Sensitive method for the detection of infectious HIV in semen of seropositive individuals. J Virol Methods, 1996; 56:33–40.
8.
GuptaP, CollinsKB, RatnerDet al.Memory CD4+ T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol, 2002; 76:9868–9876.
9.
Garcia-LermaJG, OttenRA, QariSHet al.Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med, 2008; 5:e28.
10.
JespersVA, Van RoeyJM, BeetsGIet al.Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr, 2007; 44:154–158.
11.
RosenRK, MorrowKM, Carballo-DieguezAet al.Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: A mixed-methods study. J Womens Health (Larchmt), 2008; 17:383–392.
12.
WoolfsonAD, MalcolmRK, MorrowRJet al.Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm, 2006; 325:82–89.
13.
Abdool KarimQ, Abdool KarimSS, FrohlichJAet al.Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010; 329:1168–1174[erratum in Science 2011;333:524].
14.
KetasTJ, SchaderSM, ZuritaJet al.Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology, 2007; 364:431–440.
15.
VeazeyRS, KlassePJ, SchaderSMet al.Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion. Nature, 2005; 438:99–102.
16.
Lackman-SmithC, OsterlingC, LuckenbaughKet al.Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother, 2008; 52:1768–1781.
17.
ColeAM, HongT, BooLMet al.Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA, 2002; 99:1813–1818.
18.
MunkC, WeiG, YangOOet al.The θ-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses, 2003; 19:875–881.
19.
OwenSM, RudolphDL, WangWet al.RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retroviruses, 2004; 20:1157–1165.
20.
ColeAM, PattonDL, RohanLCet al.The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One, 2010; 5:e15111.
21.
ColeAL, YangOO, WarrenADet al.HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J Immunol, 2006; 176:6900–6905.
22.
CloydMW, MooreBE. Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates. Virology, 1990; 174:103–116.
23.
BuckheitRWJr, SwanstromR. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res Hum Retroviruses, 1991; 7:295–302.
24.
SassiAB, CostMR, ColeALet al.Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product. Antimicrob Agents Chemother, 2011; 55:2282–2289.
25.
Gruszecka-KowalikE, HaugwitzRD, ZalkowLH. Quinobene, a new potent anti-HIV agent. Biochem Biophys Res Commun, 1992; 187:1409–1417.
26.
HallidaySM, Lackman-SmithC, BaderJPet al.Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene. Antiviral Res, 1996; 33:41–53.
27.
PhillipsDM, TanX, Pearce-PrattRet al.An assay for HIV infection of cultured human cervix-derived cells. J Virol Methods, 1995; 52:1–13.
28.
OkamotoM, ByrnR, EyreRCet al.Seminal plasma induces programmed cell death in cultured peripheral blood mononuclear cells. AIDS Res Hum Retroviruses, 2002; 18:797–803.
29.
ShattockRJ, MooreJP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol, 2003; 1:25–34.
30.
OwenDH, KatzDF. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl, 2005; 26:459–469.
